These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 25309325)

  • 1. Fingolimod for the treatment of neurological diseases-state of play and future perspectives.
    Brunkhorst R; Vutukuri R; Pfeilschifter W
    Front Cell Neurosci; 2014; 8():283. PubMed ID: 25309325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J; Hartung HP
    Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.
    Lucaciu A; Brunkhorst R; Pfeilschifter JM; Pfeilschifter W; Subburayalu J
    Cells; 2020 Jun; 9(6):. PubMed ID: 32580348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment.
    Leo A; Citraro R; Marra R; Palma E; Paola EDD; Constanti A; De Sarro G; Russo E
    CNS Neurol Disord Drug Targets; 2017; 16(3):311-325. PubMed ID: 27823573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
    Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
    PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second generation S1P pathway modulators: research strategies and clinical developments.
    Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
    Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
    Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
    Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases.
    Stepanovska B; Huwiler A
    Pharmacol Res; 2020 Apr; 154():104170. PubMed ID: 30776422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets.
    Melendez AJ
    Biochim Biophys Acta; 2008 Jan; 1784(1):66-75. PubMed ID: 17913601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.
    Salas-Perdomo A; Miró-Mur F; Gallizioli M; Brait VH; Justicia C; Meissner A; Urra X; Chamorro A; Planas AM
    Sci Rep; 2019 Jun; 9(1):8309. PubMed ID: 31165772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on sphingosine-1-phosphate receptor 1 modulators.
    Marciniak A; Camp SM; Garcia JGN; Polt R
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3585-3591. PubMed ID: 30409535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of sphingosine kinase localization in sphingolipid signaling.
    Wattenberg BW
    World J Biol Chem; 2010 Dec; 1(12):362-8. PubMed ID: 21537471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingolipids in neurodegeneration (with focus on ceramide and S1P).
    Wang G; Bieberich E
    Adv Biol Regul; 2018 Dec; 70():51-64. PubMed ID: 30287225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingosine 1-phosphate but not Fingolimod protects neurons against excitotoxic cell death by inducing neurotrophic gene expression in astrocytes.
    Tran C; Heng B; Teo JD; Humphrey SJ; Qi Y; Couttas TA; Stefen H; Brettle M; Fath T; Guillemin GJ; Don AS
    J Neurochem; 2020 Apr; 153(2):173-188. PubMed ID: 31742704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.
    Chiba K; Adachi K
    Pharmaceuticals (Basel); 2012 May; 5(5):514-28. PubMed ID: 24281561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P
    Stepanovska Tanturovska B; Zivkovic A; Imeri F; Homann T; Kleuser B; Stark H; Huwiler A
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.